Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 2006 results for nice guidelines

  1. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

  2. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .

  3. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  4. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  5. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

  6. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

  7. Breathlessness

    Discontinued Reference number: GID-NG10387

  8. Alpha-Stim AID for anxiety disorders (HTG570)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

  9. Mortality: respiratory (IND281)

    This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  10. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

  11. Haemochromatosis

    Discontinued Reference number: GID-NG10287

  12. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  13. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  14. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  15. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375